Life sciences product developer Senetek says it has initiated trials that will determine the efficacy of its Pyratine 6 compound on acne Rosacea, having evaluated positive results through separate trials comparing it to Kinetin, the company’s original anti-aging active ingredient.
Senetek says it has carried out an independent analysis that evaluated the effectiveness of its second generation cytokinin, Pyratine 6, against the original anti-aging ingredient, comparing results of separate clinical studies.
The results of the analysis showed that the subjects in the Pyratine 6 clinical trial demonstrated that, compared to Kinetin, it was significantly more effective as an anti-aging ingredient.
Subjects in the trial reported that over an eight week period the appearance of wrinkles improved by 22 per cent with Pyratine 6, whereas only a 2 per cent improvement was reported for Kinetin.
Likewise, over the same period, skin roughness improved by 86 per cent with Pyratine 6, compared to only 35 per cent for Kinetin, and overall aging improved by 24 per cent with Pyratine 6, compared to just 3 per cent with Kinetin.
The results of the trial led to NOVA dermal phase meter evaluations being carried out on the Pyratine 6 compound to determine the effects on reductions in skin redness and acne.
These tests showed improvements in skin moisture of 35 per cent over eight weeks and 41 per cent over 12 weeks, while redness was reduced by 42 per cent over eight weeks and 62 per cent over 12 weeks.
Likewise the compound was said to be well tolerated by all the subjects, producing no notable skin irritations or allergic reactions.
“The data collected through the comparative analysis of Pyratine 6 and Kinetin has given us significant reason to focus our efforts on taking the strategic steps necessary to launch Pyratine 6 commercially as an anti-aging compound as well as initiate clinical trials to prove that Pyratine 6 can also be used as an effective treatment for Acne Rosacea,” said Frank Massino, Senetek CEO.
The company says that following the results of its trials, an IRB-approved pilot clinical study has now been initiated to determine the efficacy of Pyratine 6 as a treatment for Rosacea, which will be conducted at the University of California.
The outcome of these trials has also influenced a decision by one of the company’s prospective licensees, which is a major cosmetics company, to commence separate clinical trials to determine the efficacy of Pyratine 6 for both skin whitening and acne treatments
